Martinez Bueno A, Molina MA, Fielding A, et al. Disruptive mutations in TP53 associate with survival benefit in a PARPi trial in ovarian cancer. ESMO 2017, abstract LBA42.
Neoadjuvant pertuzumab plus trastuzumab met of zonder chemotherapie: 5-jaarsoverlevingsdata
jun 2022 | Borstkanker